Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 6, Issue 1, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofy356
Keywords
HBV; CD20; liver; biologics; entecavir; prophylaxis
Categories
Funding
- Sapienza Universita di Roma
Ask authors/readers for more resources
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients. More studies are needed to assess the optimal management of HBV reactivation in MS patients on ocrelizumab treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available